The estimated Net Worth of Mark L Lewis is at least $6.22 Миллион dollars as of 1 November 2013. Mark Lewis owns over 5,000 units of Illumina Inc stock worth over $6,221,153 and over the last 12 years Mark sold ILMN stock worth over $0.
Mark has made over 6 trades of the Illumina Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Mark exercised 5,000 units of ILMN stock worth $185,200 on 1 November 2013.
The largest trade Mark's ever made was exercising 24,500 units of Illumina Inc stock on 20 December 2012 worth over $907,480. On average, Mark trades about 7,188 units every 43 days since 2012. As of 1 November 2013 Mark still owns at least 49,837 units of Illumina Inc stock.
You can see the complete history of Mark Lewis stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley и Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: